Adma Biologics Stock Price on September 6, 2024
ADMA Stock | USD 17.40 0.50 2.79% |
Below is the normalized historical share price chart for ADMA Biologics extending back to October 17, 2013. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of ADMA Biologics stands at 17.40, as last reported on the 22nd of December, with the highest price reaching 17.96 and the lowest price hitting 17.08 during the day.
If you're considering investing in ADMA Stock, it is important to understand the factors that can impact its price. ADMA Biologics secures Sharpe Ratio (or Efficiency) of -0.0264, which signifies that the company had a -0.0264% return per unit of return volatility over the last 3 months. ADMA Biologics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm ADMA Biologics' Mean Deviation of 2.73, coefficient of variation of (4,720), and Risk Adjusted Performance of (0.01) to double-check the risk estimate we provide.
At present, ADMA Biologics' Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 345.6 M, whereas Common Stock Total Equity is forecasted to decline to about 19 K. . At present, ADMA Biologics' Price Book Value Ratio is projected to drop based on the last few years of reporting. The current year's Price Earnings To Growth Ratio is expected to grow to 0.54, whereas Price To Sales Ratio is forecasted to decline to 3.72. ADMA Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 17th of October 2013 | 200 Day MA 13.584 | 50 Day MA 18.831 | Beta 0.645 |
ADMA |
Sharpe Ratio = -0.0264
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | ADMA |
Estimated Market Risk
4.49 actual daily | 39 61% of assets are more volatile |
Expected Return
-0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ADMA Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ADMA Biologics by adding ADMA Biologics to a well-diversified portfolio.
Price Book 17.7377 | Enterprise Value Ebitda 41.8677 | Price Sales 10.7447 | Shares Float 232.1 M | Wall Street Target Price 24.246 |
Related Headline
89bio Headline on 6th of September 2024
Disposition of 16527 shares by Rohan Palekar of 89bio at 18.... by Rohan Palekar
Filed transaction by 89bio Inc Director, Officer Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
ADMA Biologics Valuation on September 6, 2024
It is possible to determine the worth of ADMA Biologics on a given historical date. On September 6, 2024 ADMA was worth 16.73 at the beginning of the trading date compared to the closed value of 16.26. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of ADMA Biologics stock. Still, in general, we apply an absolute valuation method to find ADMA Biologics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of ADMA Biologics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against ADMA Biologics' related companies.
Open | High | Low | Close | Volume | |
16.79 | 16.79 | 16.32 | 16.74 | 2,147,483 | |
09/06/2024 | 16.73 | 16.94 | 16.07 | 16.26 | 3,122,335 |
17.50 | 19.34 | 17.48 | 18.38 | 9,460,273 |
Backtest ADMA Biologics | | | ADMA Biologics History | | | ADMA Biologics Valuation | Previous | Next |
ADMA Biologics Trading Date Momentum on September 6, 2024
On September 09 2024 ADMA Biologics was traded for 18.38 at the closing time. The top price for the day was 19.34 and the lowest listed price was 17.48 . The trading volume for the day was 9.5 M. The trading history from September 9, 2024 was a factor to the next trading day price jump. The overall trading delta against the next closing price was 13.04% . The overall trading delta against the current closing price is 12.36% . |
ADMA Biologics Fundamentals Correlations and Trends
By evaluating ADMA Biologics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among ADMA Biologics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. ADMA financial account trend analysis is a perfect complement when working with valuation or volatility modules.About ADMA Biologics Stock history
ADMA Biologics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for ADMA is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in ADMA Biologics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing ADMA Biologics stock prices may prove useful in developing a viable investing in ADMA Biologics
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 224 M | 235.2 M | |
Net Loss | -59.3 M | -62.3 M |
ADMA Biologics Quarterly Net Working Capital |
|
ADMA Biologics Stock Technical Analysis
ADMA Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
ADMA Biologics Period Price Range
Low | December 22, 2024
| High |
0.00 | 0.00 |
ADMA Biologics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
ADMA Biologics December 22, 2024 Market Strength
Market strength indicators help investors to evaluate how ADMA Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ADMA Biologics shares will generate the highest return on investment. By undertsting and applying ADMA Biologics stock market strength indicators, traders can identify ADMA Biologics entry and exit signals to maximize returns
ADMA Biologics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for ADMA Biologics' price direction in advance. Along with the technical and fundamental analysis of ADMA Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of ADMA to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | (0.01) | |||
Jensen Alpha | (0.14) | |||
Total Risk Alpha | (0.23) | |||
Treynor Ratio | (0.07) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
CEOs Directory Screen CEOs from public companies around the world | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |